Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/39949

Title:	Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Authors:	Martinez-Lopez, J Sanchez-Vega, B Barrio, S Cuenca, I Ruiz-Heredia, Y Alonso, R Rapado, I Marin, C Cedena, M-T Paiva, B Puig, N Mateos, M-V Ayala, R Hernández, M-T Jimenez, C Rosiñol, L Martínez, R Teruel, A-I Gutiérrez, N Martin-Ramos, M-L Oriol, A Bargay, J Bladé, J San-Miguel, J Garcia-Sanz, R Lahuerta, J-J View more
Mesh:	Aged Antineoplastic Combined Chemotherapy Protocols Female High-Throughput Nucleotide Sequencing Humans Male Monitoring, Physiologic Multiple Myeloma Neoplasm, Residual Survival Analysis View more
Issue Date:	2017
Citation:	Leukemia.2017 06;(31)6:1446-1449
PMID:	28210002
URI:	https://hdl.handle.net/20.500.12530/39949
Rights:	openAccess
Appears in Collections:	Hospitales > H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Clínico San Carlos > Artículos

Files in This Item:

File	Description	Size	Format
PMC5467041.pdf		219.62 kB	Adobe PDF	View/Open